Sensyne names partners for USA health products launch

Sensyne

Sensyne Health plc, the British clinical AI technology company, today announces the name of its partners for the launch and sale of its digital health software products in the United States of America. Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.

The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.

These products were originally invented and developed in the UK’s NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne’s unique partnership model. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: “Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”